View in EDS HTML Full Text PDF Full Text

Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.

Saved in:
Bibliographic Details
Title: Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.
Authors: Mallett G; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Kamala O; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Pappworth IY; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Smith-Jackson K; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Gibson BG; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Asif M; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Denton H; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Cox C; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom., Walsh P; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Kavanagh D; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom., Marchbank KJ; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.
Source: Frontiers in immunology [Front Immunol] 2026 Apr 28; Vol. 17, pp. 1828298. Date of Electronic Publication: 2026 Apr 28 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42131334
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Mallett+G%22">Mallett G</searchLink>; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kamala+O%22">Kamala O</searchLink>; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Pappworth+IY%22">Pappworth IY</searchLink>; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Smith-Jackson+K%22">Smith-Jackson K</searchLink>; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Gibson+BG%22">Gibson BG</searchLink>; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Asif+M%22">Asif M</searchLink>; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Denton+H%22">Denton H</searchLink>; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Cox+C%22">Cox C</searchLink>; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Walsh+P%22">Walsh P</searchLink>; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kavanagh+D%22">Kavanagh D</searchLink>; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Marchbank+KJ%22">Marchbank KJ</searchLink>; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, The Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2026 Apr 28; Vol. 17, pp. 1828298. <i>Date of Electronic Publication: </i>2026 Apr 28 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42131334
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2026.1828298
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1828298
    Titles:
      – TitleFull: Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mallett G
      – PersonEntity:
          Name:
            NameFull: Kamala O
      – PersonEntity:
          Name:
            NameFull: Pappworth IY
      – PersonEntity:
          Name:
            NameFull: Smith-Jackson K
      – PersonEntity:
          Name:
            NameFull: Gibson BG
      – PersonEntity:
          Name:
            NameFull: Asif M
      – PersonEntity:
          Name:
            NameFull: Denton H
      – PersonEntity:
          Name:
            NameFull: Cox C
      – PersonEntity:
          Name:
            NameFull: Walsh P
      – PersonEntity:
          Name:
            NameFull: Kavanagh D
      – PersonEntity:
          Name:
            NameFull: Marchbank KJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 04
              Text: 2026 Apr 28
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 17
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1